Simplify Asset Management Inc. Acquires Shares of 8,753 Cencora, Inc. $COR

Simplify Asset Management Inc. acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,753 shares of the company’s stock, valued at approximately $2,625,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of COR. Atlantic Edge Private Wealth Management LLC boosted its stake in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the period. Costello Asset Management INC purchased a new stake in shares of Cencora in the first quarter valued at $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Cencora in the 1st quarter worth about $39,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Cencora during the 2nd quarter worth about $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Cencora during the second quarter valued at approximately $61,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on COR shares. UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday. Mizuho lifted their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Morgan Stanley set a $330.00 price objective on Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Evercore ISI set a $400.00 price objective on Cencora and gave the stock an “outperform” rating in a report on Thursday. Finally, TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $355.91.

Cencora Price Performance

Shares of COR stock opened at $364.40 on Tuesday. The firm has a market capitalization of $70.65 billion, a price-to-earnings ratio of 37.49, a PEG ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The stock’s 50-day simple moving average is $315.73 and its 200-day simple moving average is $300.12. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $366.00.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the prior year, the firm earned $3.34 EPS. The firm’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is presently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.